Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...
Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...
The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common ...
New center will use cutting-edge AI to accelerate the creation of life-saving medicines AI Small Molecule Drug Discovery ...